Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230035/S006

AGENT Paclitaxel-Coated Balloon Catheter

BOSTON SCIENTIFIC CORPORATION · Decision date Feb 11, 2026

FDA DECISIONP230035/S006

What did the FDA approve?

FDA records P230035/S006 as a supplement to PMA P230035, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Feb 11, 2026.

FDA approval order statement

a manufacturing site change to include Boston Scientific Ltd., located at Ballybrit Business Park, Galway, Ireland, for drug coating manufacturing, packaging and labeling for the Agent Monorail Paclitaxel Coated Balloon Catheter
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Feb 11, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230035/S006
Regulatory pathway
PMA supplement
Product code
OOB
Decision code
APPR
Decision date
Feb 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting percutaneous transluminal coronary angioplasty catheter.

Product code
OOB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230035/S006 received

    Application receipt date recorded by FDA.

  2. P230035/S007 · Related supplement

    AGENT Paclitaxel-Coated Balloon Catheter

  3. P230035/S006 · FDA decision

    Normal 180 Day Track No User Fee

  4. P230035/S009 · Related supplement

    AGENT Paclitaxel-Coated Balloon Catheter

  5. P230035/S010 · Related supplement

    AGENT Paclitaxel-Coated Balloon Catheter

Timeline entries are records held by MedtechLedger for P230035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230035

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 24, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 30, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 28, 2026FDA

Explore the linked device profile

Other records with product code OOB

Product / regulatory recordCompanyPathwayDecision dateSource
MedAlliance, LLCPMA supplementNov 6, 2026FDA
MedAlliance, LLCPMA approvalSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records